MX2010004688A - Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a. - Google Patents

Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a.

Info

Publication number
MX2010004688A
MX2010004688A MX2010004688A MX2010004688A MX2010004688A MX 2010004688 A MX2010004688 A MX 2010004688A MX 2010004688 A MX2010004688 A MX 2010004688A MX 2010004688 A MX2010004688 A MX 2010004688A MX 2010004688 A MX2010004688 A MX 2010004688A
Authority
MX
Mexico
Prior art keywords
compounds
therapeutic uses
ht1a activity
sert
combined
Prior art date
Application number
MX2010004688A
Other languages
English (en)
Inventor
Nicholas Moore
Marianne Dragheim
Aneil Batra
Jin Chon
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004688(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2010004688A publication Critical patent/MX2010004688A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proveen nuevos usos farmacéuticos de 1-[2-(2,4-dimetilfenilsulf anil)fenil]piperazina y de sus sales aceptables para uso farmacéutico.
MX2010004688A 2007-11-13 2008-11-12 Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a. MX2010004688A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98771007P 2007-11-13 2007-11-13
DKPA200701607 2007-11-13
US1372207P 2007-12-14 2007-12-14
DKPA200701788 2007-12-14
US9784008P 2008-09-17 2008-09-17
DKPA200801300 2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (1)

Publication Number Publication Date
MX2010004688A true MX2010004688A (es) 2010-09-09

Family

ID=40170671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004688A MX2010004688A (es) 2007-11-13 2008-11-12 Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a.

Country Status (30)

Country Link
US (5) US9278096B2 (es)
EP (3) EP2431039B1 (es)
JP (2) JP5603244B2 (es)
KR (1) KR101536023B1 (es)
CN (1) CN102014908A (es)
AR (1) AR069260A1 (es)
AT (1) ATE537829T1 (es)
AU (1) AU2008323390B2 (es)
BR (1) BRPI0820474B8 (es)
CA (1) CA2705163C (es)
CL (1) CL2008003363A1 (es)
CO (1) CO6270322A2 (es)
CY (2) CY1112646T1 (es)
DK (2) DK2431039T3 (es)
EA (1) EA027783B1 (es)
ES (2) ES2379419T5 (es)
HR (2) HRP20120144T4 (es)
HU (1) HUE029588T2 (es)
IL (1) IL205466A (es)
LT (1) LT2431039T (es)
MX (1) MX2010004688A (es)
NZ (1) NZ585247A (es)
PL (2) PL2219647T3 (es)
PT (2) PT2219647E (es)
RS (2) RS52256B2 (es)
SG (1) SG10201405001XA (es)
SI (2) SI2219647T2 (es)
TW (1) TW200932233A (es)
WO (1) WO2009062517A1 (es)
ZA (1) ZA201003350B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CA2769872A1 (en) * 2009-08-24 2011-03-03 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
BR112013018898B1 (pt) * 2011-01-27 2021-10-05 Neuren Pharmaceuticals Limited Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo
WO2013012038A1 (ja) 2011-07-21 2013-01-24 学校法人名城大学 うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
NZ708595A (en) * 2012-12-13 2019-06-28 H Lundbeck As Compositions comprising vortioxetine and donepezil
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
WO2014191548A1 (en) * 2013-05-31 2014-12-04 Lek Pharmaceuticals D.D. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CA2933733A1 (en) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
AU2016296205B2 (en) * 2015-07-17 2021-11-11 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
SG11201810644TA (en) 2016-07-01 2018-12-28 H Lundbeck As Vortioxetine dosing regimes for fast onset of antidepressant effect
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CA2467118A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
US7732463B2 (en) 2003-04-04 2010-06-08 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CA2769872A1 (en) 2009-08-24 2011-03-03 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Also Published As

Publication number Publication date
AU2008323390B2 (en) 2013-10-24
KR101536023B9 (ko) 2023-03-29
JP5841636B2 (ja) 2016-01-13
PL2431039T3 (pl) 2016-12-30
US20160228430A1 (en) 2016-08-11
EP2431039A1 (en) 2012-03-21
DK2219647T3 (da) 2012-03-19
ATE537829T1 (de) 2012-01-15
AU2008323390A1 (en) 2009-05-22
US20210093631A1 (en) 2021-04-01
CN102014908A (zh) 2011-04-13
EP2219647B2 (en) 2020-07-29
NZ585247A (en) 2012-03-30
EP3115050A1 (en) 2017-01-11
ES2379419T3 (es) 2012-04-25
EA027783B1 (ru) 2017-09-29
EP2219647B1 (en) 2011-12-21
DK2219647T4 (da) 2020-09-28
WO2009062517A1 (en) 2009-05-22
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
ES2379419T5 (es) 2021-05-04
BRPI0820474A2 (pt) 2017-05-23
SI2219647T1 (sl) 2012-06-29
CY1117978T1 (el) 2017-05-17
PT2431039T (pt) 2016-09-29
EA201070598A1 (ru) 2010-10-29
RS55147B1 (sr) 2016-12-30
US20110201617A1 (en) 2011-08-18
CL2008003363A1 (es) 2009-06-05
RS52256B2 (sr) 2020-11-30
US9278096B2 (en) 2016-03-08
HRP20161121T1 (hr) 2017-01-27
RS52256B (en) 2012-10-31
AR069260A1 (es) 2010-01-06
BRPI0820474B1 (pt) 2020-08-04
CA2705163C (en) 2013-02-12
PT2219647E (pt) 2012-03-16
HRP20120144T1 (en) 2012-04-30
IL205466A0 (en) 2010-12-30
US9744166B2 (en) 2017-08-29
SI2431039T1 (sl) 2017-01-31
ES2591110T3 (es) 2016-11-24
TW200932233A (en) 2009-08-01
JP2011503125A (ja) 2011-01-27
LT2431039T (lt) 2016-10-10
US11628166B2 (en) 2023-04-18
SI2219647T2 (sl) 2020-11-30
EP2431039B1 (en) 2016-07-20
KR20100099115A (ko) 2010-09-10
KR101536023B1 (ko) 2015-07-10
HUE029588T2 (en) 2017-03-28
CO6270322A2 (es) 2011-04-20
CY1112646T1 (el) 2016-02-10
US20240082239A1 (en) 2024-03-14
JP2014193891A (ja) 2014-10-09
JP5603244B2 (ja) 2014-10-08
CA2705163A1 (en) 2009-05-22
DK2431039T3 (en) 2016-09-26
BRPI0820474B8 (pt) 2021-05-25
ZA201003350B (en) 2011-08-31
HRP20120144T4 (hr) 2020-11-13
EP2219647A1 (en) 2010-08-25
IL205466A (en) 2014-06-30
SG10201405001XA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
MX2010004688A (es) Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a.
HRP20120173T1 (en) 1- ¦[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
UA97392C2 (ru) 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин как соединение с комбинированной активностью в отношении обратного захвата серотонина, 5-нт3 и 5-нт1a для лечения боли
MX2009014208A (es) Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
EA200971046A1 (ru) Новые соли пиперазина в качестве d/d-антагонистов
RS50624B (sr) Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina
TN2011000504A1 (en) Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl) phenyl] piperazine
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
GEP20135730B (en) Trans-4-{2-[4-(2,3-dichlorophe-nyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treatment of schizophrenia
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
RS53521B1 (en) PREPARATION AND THERAPY APPLICATIONS (2S, 3R) -N-2 - ((3-pyridinyl) methyl) -1-AZABICYCLO [2.2.2] OCT-3-IL) -3,5-DIFLUOROBENZAMIDE
SMT201300108B (it) Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
GEP20115222B (en) New pharmaceutical compounds
UA101323C2 (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for the treatment of acute mania
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
TW200732304A (en) Piperidine derivatives
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
NZ600266A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
RS54293B1 (en) PHARMACEUTICAL COMBINATION
TW200700390A (en) Metabolites for nk-1 antagonists for emesis
MX349724B (es) Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperaz ina.
EA201000611A1 (ru) 4,4-дизамещенные пиперидины
UA101341C2 (ru) Терапевтические применения соединений, которые имеют комбинированную активность в отношении sert, 5-нт3 и 5-нт1a
MY145425A (en) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted
HC Change of company name or juridical status